Alx oncology announces first patient dosed in aspen-07, a phase 1 study of evorpacept for the treatment of patients with urothelial cancer

South san francisco, calif., feb. 16, 2023 (globe newswire) -- alx oncology holdings inc., (“alx oncology”) (nasdaq: alxo), a clinical-stage immuno-oncology company developing therapies that block the cd47 checkpoint pathway, today announced the first patient has been dosed in the aspen-07 study evaluating evorpacept, a next generation cd47 blocker, in combination with padcev® (enfortumab vedotin-ejfv), an antibody drug conjugate (“adc”), in patients with urothelial cancer (“uc”).
ALXO Ratings Summary
ALXO Quant Ranking